Nakom Mite (Carbidopa, Levodopa)

Carbidopa/Levodopa, the active ingredient in Nakom Mite, is an antiparkinson agent presented as an oral tablet for oral use. It treats Parkinson's disease and Parkinsonian syndrome in adult patients by restoring dopamine levels in the brain. The combination leverages carbidopa to inhibit peripheral metabolism, allowing a greater proportion of levodopa to reach the central nervous system.

GNH USA supplies Nakom Mite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice (GDP) standards, ensuring product quality, traceability, and compliance with EU regulatory requirements for export.

Carbidopa/Levodopa is used in the management of Parkinsonian disorders to improve motor function. - Parkinson's disease: reduces bradykinesia, rigidity, and tremor, thereby improving gait, balance, and overall daily functioning. - Parkinsonian syndrome: alleviates motor symptoms such as stiffness and slowed movements in secondary Parkinsonism, supporting better mobility. - Levodopa-responsive Parkinsonism: provides symptomatic relief by increasing central dopamine, helping patients with dopamine‑deficient states regain functional ability. - Drug‑induced Parkinsonism: improves motor deficits caused by dopamine‑blocking agents, facilitating smoother movement. - Dopa‑responsive dystonia: reduces abnormal muscle tone and improves posture in patients with this rare condition.

Carbidopa/Levodopa may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: upset stomach often occurring after the first doses. - Vomiting: expulsion of stomach contents, may accompany nausea. - Orthostatic hypotension: drop in blood pressure upon standing, causing light‑headedness. - Dizziness: sensation of spinning or loss of balance. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Dyskinesia (involuntary movements): excessive, uncontrolled muscle movements. - Hallucinations or psychosis: visual or auditory disturbances, confusion. - Neuroleptic malignant syndrome: rare life‑threatening reaction with fever and muscle rigidity.

When prescribing Carbidopa/Levodopa, clinicians should consider several precautionary measures to minimize risks. - Dose titration: start with the lowest effective dose and increase gradually under medical supervision. - Blood pressure monitoring: watch for orthostatic hypotension, especially in elderly patients. - Psychiatric assessment: monitor for hallucinations, confusion, or mood changes during therapy. - Contraindications: avoid use in patients with narrow‑angle glaucoma or known hypersensitivity to the components. - Pregnancy and lactation: prescribe only if potential benefit justifies potential risk to the fetus or infant. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Carbidopa/Levodopa can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may precipitate hypertensive crisis. - Antipsychotics (e.g., haloperidol): can diminish antiparkinson effect. - Anticholinergic agents: may mask motor symptom changes.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: increased risk of serotonin syndrome. - Diuretics: may exacerbate orthostatic hypotension. - Iron or calcium supplements: reduce levodopa absorption if taken simultaneously.